Cost of Revenue Comparison: Teva Pharmaceutical Industries Limited vs HUTCHMED (China) Limited

Cost of Revenue: A Tale of Two Pharmaceutical Giants

In the ever-evolving pharmaceutical industry, understanding cost structures is crucial for investors and stakeholders. This analysis compares the cost of revenue for Teva Pharmaceutical Industries Limited and HUTCHMED (China) Limited from 2014 to 2023. Over this period, Teva's cost of revenue consistently dwarfed that of HUTCHMED, averaging around 9.2 billion annually, while HUTCHMED's figures hovered around 196 million.

Key Insights

• Teva's Dominance: Teva's cost of revenue peaked in 2017, reaching approximately 11.6 billion, reflecting its expansive operations and market reach.
• HUTCHMED's Growth: Despite being smaller, HUTCHMED showed a remarkable growth trajectory, with its cost of revenue increasing by over 400% from 2014 to 2023.
• Market Dynamics: The data highlights the contrasting scales and strategies of these companies, with Teva focusing on volume and HUTCHMED on strategic growth.

This comparison underscores the diverse approaches within the pharmaceutical sector, offering valuable insights for market analysts and investors.